SCHEMBL23950756

SCHEMBL23950756

CC(CO)n1cnc2c(-c3ccc(Cl)cc3)nc(-c3cccnc3)cc2c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSD A5PKW4 3/20 0.41
CYP2C9 P11712 4/20 0.39
CYP2C19 P33261 4/20 0.39
CYP3A4 P08684 3/20 0.39
CYP1A2 P05177 2/20 0.39
GAA P10253 1/20 0.39
KDM4E B2RXH2 1/20 0.37
POLB P06746 1/20 0.37
NPY5R Q15761 1/20 0.37
MAP3K5 Q99683 1/20 0.37
CYP19A1 P11511 1/20 0.36
CYP2E1 P05181 2/20 0.35
CYP2A6 P11509 2/20 0.35
CYP2B6 P20813 2/20 0.35
MAPT P10636 1/20 0.35
PDE4A P27815 2/20 0.35
PDE4C Q08493 2/20 0.35
PDE4D Q08499 2/20 0.35
RXFP1 Q9HBX9 1/20 0.35
SLC2A1 P11166 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30101939 1.00 PSD (0.41) PSDCYP2C9CYP2C19CYP3A4CYP1A2
SCHEMBL23390221 0.97 PSD (0.40) PSDCYP2C9CYP2C19CYP3A4CYP1A2
SCHEMBL30101948 0.97 PSD (0.40) PSDCYP2C9CYP2C19CYP3A4CYP1A2
SCHEMBL23390225 0.97 PSD (0.40) PSDCYP2C9CYP2C19CYP3A4CYP1A2
SCHEMBL23950594 0.96 PSD (0.40) PSDCYP2C9CYP2C19CYP3A4CYP1A2
SCHEMBL23390306 0.92 CYP2A6 (0.39) CYP2C9CYP2C19CYP3A4KDM4EMAP3K5
SCHEMBL23390302 0.92 CYP2A6 (0.39) CYP2C9CYP2C19CYP3A4KDM4EMAP3K5
SCHEMBL23390503 0.89 CYP2A6 (0.37) CYP2C9CYP2C19CYP3A4KDM4EMAP3K5
SCHEMBL23390432 0.89 PIK3CA (0.41) CYP2C9CYP2C19CYP3A4KDM4EMAP3K5
SCHEMBL23390500 0.89 CYP2A6 (0.37) CYP2C9CYP2C19CYP3A4KDM4EMAP3K5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230147257-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS DONG-A ST CO., LTD. (KR) 2023-05-11 US disclosed
US-20230147257-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS DONG-A ST CO., LTD. (KR) 2023-05-11 US disclosed
WO-2021210970-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS DONG-A ST CO., LTD. (KR) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230147257-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS AHR, ARNT, AIPL1 PSD 3850/4885CYP2C9 348/4885CYP2C19 225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.